Financials data is unavailable for this security.
Cash flow in USDView more
In 2023, Entrada Therapeutics Inc increased its cash reserves by 45.71%, or 22.45m. The company earned 139.80m from its operations for a Cash Flow Margin of 108.36%. In addition the company generated 21.04m cash from financing while 138.40m was spent on investing.
Cash flow per share | 3.12 |
---|---|
Price/Cash flow per share | 4.71 |
Book value per share | 11.57 |
---|---|
Tangible book value per share | 11.57 |
More ▼
Balance sheet in USDView more
Current ratio | 5.70 |
---|---|
Quick ratio | -- |
Total debt/total equity | 0.00 |
---|---|
Total debt/total capital | 0.00 |
More ▼